Inify Laboratories - mandatory notification of trade

Inify Laboratories disclosed allocations of new shares to primary insiders in a repair issue announced 9 December 2025: Monsun AS (closely associated with board member Magne Jordanger) was allocated 898,204 shares and, through Monsun AS and Gallivant S.a.r.l., Jordanger will hold 76,868,249 shares subject to completion of the Repair Issue and the Private Placement. Other allocations: chairman Olof Sandén 43,139 shares (holding post-close 159,979); board member Martin Ingvar 67,132 (283,195); CEO Fredrik Palm 36,564 (139,613); CFO Ann‑Charlotte Linderoth 26,433 (99,433). All allocations were at the subscription price and disclosed under EU Market Abuse Regulation and Norwegian Securities Trading Act requirements.

Analysis

Market structure: Insider participation in the repair issue (notably Monsun AS taking ~898k shares and board members increasing stakes) signals management wants to avoid reputational dilution and provides a short-term demand anchor, but the immediate net effect is increased float and likely downward pressure on price until the Repair Issue and Private Placement close (expect 0–30% sell/overhang in days). Competitively, additional capital can accelerate roll‑out of Inify's scalable digital pathology labs and AI stack, improving local pricing power in targeted niches (prostate/gastroenterology) vs regional labs if execution converts into +10–30% capacity growth within 12–24 months.

Risk assessment: Tail risks include adverse regulatory findings for AI-assisted diagnostics, reimbursement cuts, or lab accreditation failures that could produce >70% valuation drawdowns; operational scale‑up failure or missed private placement closes are 30–50% probability events in small-cap diagnostics. Timeframe split: immediate (days) = share overhang and volatility; short (weeks–months) = cash runway clarity and placement terms; long (quarters–years) = revenue traction, margins and clinical validation. Hidden dependencies: revenue depends on hospital contracts and public payor reimbursement and on CE/UKCA approvals; catalysts include placement close (within 30–60 days), publication of clinical validation, and new lab openings.

Trade implications: Direct play — establish a tactical small long in INIFY (ticker INIFY) sized 1–3% of NAV only after the Repair Issue and Private Placement close and cash runway ≥12 months; set stop-loss at −30% from entry and target +80–150% within 12–24 months if operational milestones hit. Options — if liquid, buy 9–12 month calls 40–60% OTM sized <0.5% NAV as a binary asymmetric bet; alternatively buy 6‑month puts (cost <0.5% NAV) to hedge existing exposure if downside >30% is unacceptable. Pair trade — long INIFY vs short Hologic (HOLX) sized 1:1 dollar exposure to isolate execution risk; rotate capital into diagnostics small-caps only after positive clinical/regulatory news.

Contrarian angles: The market may overweight insider buying as an unqualified positive; instead treat it as a pro rata participation signal that limits dilution for insiders but does not guarantee commercial execution — mispricing can arise if investors ignore cash burn metrics. Historically, rights/repair issues in small diagnostics often leave share prices depressed until tangible revenue growth (6–18 months) materializes; unintended consequence: concentrated insider ownership (>50% combined) could reduce float and liquidity, deterring institutional buyers and suppressing multiple expansion.

Key Decisions for Investors

• Establish a conditional long position in INIFY (ticker INIFY) of 1–3% NAV only after confirmation of Repair Issue and Private Placement closes and verification that cash runway ≥12 months; set an absolute stop-loss at −30% and target +80–150% within 12–24 months tied to lab rollouts and revenue milestones.
• If already long, buy 6‑month protective puts sized to cover 50% of position (cost target <0.5% NAV) or trim 25–50% if INIFY rallies >25% pre-placement close to lock-in profit and reduce execution risk exposure.
• Event-driven asymmetric bet: allocate 0.25–0.5% NAV to 9–12 month OTM calls (40–60% OTM) on INIFY as a low-cost upside play conditional on clinical validation/publication within 6–12 months; limit total options exposure to <1% NAV.
• Relative-value pair: go long INIFY (small size) and short Hologic (HOLX) equal dollar notional to isolate Inify execution risk; maintain for 6–18 months and rebalance if INIFY misses two consecutive operational milestones (lab openings, contract wins, revenue growth >+20% QoQ).
• Monitor within 30–60 days: placement subscription rate, post‑issue free float change, disclosed cash runway, and any regulatory/CE/UKCA approvals; if placement subscription <80% or cash runway <9 months, close longs and increase shorts.